Which protective effect is better, Fubitai vaccine or Kexing vaccine?
Whether it is good or bad can play a certain protective role and play a certain defensive role, mainly depending on personal choice.
At present, both Kexing vaccine and Fubitai vaccine available for vaccination are safe and effective. Vaccination is better than no vaccination. We appeal to the citizens who have made an appointment to get the second dose of vaccine in time to avoid giving up all previous efforts.
Judging from the current data, the protection rate of Fubitai vaccine will be relatively high, reaching 95%, while the protection rate of Kexing vaccine is relatively low, but the side effects will be relatively small.
The new vaccine of Kexing Company belongs to inactivated vaccine. According to experts from the Turkish Scientific Committee, the effective rate of the third phase clinical trial of novel coronavirus vaccine of Kexing Company was 83.5%, the critical protection rate was 1.000%, and there were no side effects.
Fubitai vaccine has the highest protection rate in clinical trials, and its protection effect is also supported by real data.
What are the advantages of Fubitai vaccine?
Compared with traditional vaccines, mRNA vaccine has obvious advantages and may play an important role in this epidemic:
1, no virus, no infection risk.
2. The research and development efficiency is high, and it can quickly respond to virus variation.
3. It has two mechanisms: humoral immunity and cellular immunity, and has strong immunogenicity.
4. Mass production can easily support global supply targets.
At present, Fubitai new crown vaccine has not been listed in China, but it has been opened in Hong Kong and other places, and Hong Kong citizens can be vaccinated.
Fubitai vaccine was jointly developed by China, Shanghai and Mainz. Approved by the Food and Health Bureau of the Hong Kong Special Administrative Region, it can be used for emergencies in Hong Kong. COVID-19 vaccines, like other vaccines, can only be registered after strict clinical research, and in the process of production, the relevant state departments will also make strict requirements for this, so as to ensure the safety, effectiveness and qualification of vaccines after marketing to a higher extent.